{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:32:16Z","timestamp":1773955936384,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T00:00:00Z","timestamp":1510704000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00705-017-3640-6","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T01:57:47Z","timestamp":1510711067000},"page":"467-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence of NS5B resistance-associated variants in treatment-na\u00efve Asian patients with chronic hepatitis C"],"prefix":"10.1007","volume":"163","author":[{"given":"Song","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huichun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weini","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-6688","authenticated-orcid":false,"given":"Calvin Q.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,15]]},"reference":[{"key":"3640_CR1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","unstructured":"AASLD\/IDSA HCV Guidance Panel (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932\u2013954","journal-title":"Hepatology"},{"key":"3640_CR2","doi-asserted-by":"crossref","first-page":"e6128","DOI":"10.1097\/MD.0000000000006128","volume":"96","author":"CY Chang","year":"2017","unstructured":"Chang CY, Nguyen P, Le A, Zhao C, Ahmed A, Daugherty T, Garcia G, Lutchman G, Kumari R, Nguyen MH (2017) Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine 96:e6128","journal-title":"Medicine"},{"key":"3640_CR3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3350\/cmh.2015.21.4.358","volume":"21","author":"Y Cho","year":"2015","unstructured":"Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ (2015) Sofosbuvir-based therapy for patients with chronic hepatitis C: early experience of its efficacy and safety in Korea. Clin Mol Hepatol 21:358\u2013364","journal-title":"Clin Mol Hepatol"},{"key":"3640_CR4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","volume":"61","author":"EF Donaldson","year":"2015","unstructured":"Donaldson EF, Harrington PR, O\u2019Rear JJ, Naeger LK (2015) Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61:56\u201365","journal-title":"Hepatology"},{"key":"3640_CR5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1751-2980.2012.00636.x","volume":"13","author":"ZX Dong","year":"2012","unstructured":"Dong ZX, Zhou HJ, Wang JH, Xiang XG, Zhuang Y, Guo SM, Gui HL, Zhao GD, Tang WL, Wang H, Xie Q (2012) Distribution of hepatitis C virus genotypes in Chinese patients with chronic hepatitis C: correlation with patients\u2019 characteristics and clinical parameters. J Dig Dis 13:564\u2013570","journal-title":"J Dig Dis"},{"key":"3640_CR6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"European Association for Study of Liver Diseases","year":"2015","unstructured":"European Association for Study of Liver Diseases (2015) EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63:199\u2013236","journal-title":"J Hepatol"},{"key":"3640_CR7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12985-015-0341-1","volume":"12","author":"W Ju","year":"2015","unstructured":"Ju W, Yang S, Feng S, Wang Q, Liu S, Xing H, Xie W, Zhu L, Cheng J (2015) Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. Virol J 12:109","journal-title":"Virol J"},{"key":"3640_CR8","doi-asserted-by":"crossref","first-page":"41660","DOI":"10.1038\/srep41660","volume":"7","author":"Y Kai","year":"2017","unstructured":"Kai Y, Hikita H, Morishita N, Murai K, Nakabori T, Iio S, Hagiwara H, Imai Y, Tamura S, Tsutsui S, Naito M, Nishiuchi M, Kondo Y, Kato T, Suemizu H, Yamada R, Oze T, Yakushijin T, Hiramatsu N, Sakamori R, Tatsumi T, Takehara T (2017) Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. Sci Rep 7:41660","journal-title":"Sci Rep"},{"key":"3640_CR9","doi-asserted-by":"crossref","first-page":"e0155869","DOI":"10.1371\/journal.pone.0155869","volume":"11","author":"P Kalaghatgi","year":"2016","unstructured":"Kalaghatgi P, Sikorski AM, Knops E, Rupp D, Sierra S, Heger E, Neumann-Fraune M, Beggel B, Walker A, Timm J, Walter H, Obermeier M, Kaiser R, Bartenschlager R, Lengauer T (2016) Geno2pheno[HCV]\u2014a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One 11:e0155869","journal-title":"PLoS One"},{"key":"3640_CR10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","volume":"59","author":"W Kati","year":"2015","unstructured":"Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C (2015) In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59:1505\u20131511","journal-title":"Antimicrob Agents Chemother"},{"key":"3640_CR11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2014.04.008","volume":"8","author":"TL Kieffer","year":"2014","unstructured":"Kieffer TL, George S (2014) Resistance to hepatitis C virus protease inhibitors. Curr Opin Virol 8:16\u201321","journal-title":"Curr Opin Virol"},{"key":"3640_CR12","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.3748\/wjg.v22.i40.8910","volume":"22","author":"DA Kliemann","year":"2016","unstructured":"Kliemann DA, Tovo CV, da Veiga AB, de Mattos AA, Wood C (2016) Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol 22:8910\u20138917","journal-title":"World J Gastroenterol"},{"key":"3640_CR13","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","volume":"56","author":"AM Lam","year":"2012","unstructured":"Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA (2012) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56:3359\u20133368","journal-title":"Antimicrob Agents Chemother"},{"key":"3640_CR14","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/ijms17091416","volume":"17","author":"N Marascio","year":"2016","unstructured":"Marascio N, Pavia G, Strazzulla A, Dierckx T, Cuypers L, Vrancken B, Barreca GS, Mirante T, Malanga D, Oliveira DM, Vandamme AM, Torti C, Liberto MC, Foca A, The Sinergie-Umg Study G (2016) Detection of natural resistance-associated substitutions by ion semiconductor technology in HCV1b positive, direct-acting antiviral agents-naive patients. Int J Mol Sci 17:1416","journal-title":"Int J Mol Sci"},{"key":"3640_CR15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1743-422X-10-355","volume":"10","author":"S Paolucci","year":"2013","unstructured":"Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F (2013) Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J 10:355","journal-title":"Virol J"},{"key":"3640_CR16","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1128\/AAC.02776-15","volume":"60","author":"JA Patino-Galindo","year":"2016","unstructured":"Patino-Galindo JA, Salvatierra K, Gonzalez-Candelas F, Lopez-Labrador FX (2016) Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. Antimicrob Agents Chemother 60:2402\u20132416","journal-title":"Antimicrob Agents Chemother"},{"key":"3640_CR17","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3131","author":"A Peres-da-Silva","year":"2017","unstructured":"Peres-da-Silva A, Brandao-Mello CE, Lampe E (2017) Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV. Antivir Ther. \n                        https:\/\/doi.org\/10.3851\/IMP3131\n                        \n                     (Epub ahead of print)","journal-title":"Antivir Ther"},{"key":"3640_CR18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C (2016) The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486\u2013504","journal-title":"J Hepatol"},{"key":"3640_CR19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2015.02.005","volume":"65","author":"SJ Shepherd","year":"2015","unstructured":"Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN (2015) Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol 65:50\u201353","journal-title":"J Clin Virol"},{"key":"3640_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1328-z","author":"G Suda","year":"2017","unstructured":"Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M, Umemura M, Ito J, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Tsubota A, Shimada N, Iio E, Tanaka Y, Sakamoto N (2017) Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. \n                        https:\/\/doi.org\/10.1007\/s00535-017-1328-z\n                        \n                     (Epub ahead of print)","journal-title":"J Gastroenterol"},{"key":"3640_CR21","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","volume":"213","author":"ES Svarovskaia","year":"2016","unstructured":"Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H (2016) L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis 213:1240\u20131247","journal-title":"J Infect Dis"},{"key":"3640_CR22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","volume":"209","author":"X Tong","year":"2014","unstructured":"Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Najera I (2014) In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 209:668\u2013675","journal-title":"J Infect Dis"},{"key":"3640_CR23","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/hepr.12673","volume":"46","author":"Y Uchida","year":"2016","unstructured":"Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S (2016) Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir\/asunaprevir therapy by a two-hit mechanism. Hepatol Res 46:1234\u20131246","journal-title":"Hepatol Res"},{"key":"3640_CR24","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3149","author":"S Xu","year":"2017","unstructured":"Xu S, Doehle B, Rajyaguru S, Han B, Barauskas O, Feng J, Perry J, Dvory-Sobol H, Svarovskaia ES, Miller MD, Mo H (2017) In vitro selection of resistance to sofosbuvir in HCV replicons of genotype 1 to 6. Antivir Ther. \n                        https:\/\/doi.org\/10.3851\/IMP3149\n                        \n                     (Epub ahead of print)","journal-title":"Antivir Ther"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00705-017-3640-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-017-3640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-017-3640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T02:17:25Z","timestamp":1517797045000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00705-017-3640-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,15]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3640"],"URL":"https:\/\/doi.org\/10.1007\/s00705-017-3640-6","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,15]]}}}